Market Access
Solution Spotlight: Acumetis Model Builder
Sponsored

Solution Spotlight: Acumetis Model Builder

Acumetis Model Builder is a web-based platform that generates complete, formula-linked Excel cost-effectiveness and budget impact models in minutes.

Articles
The future of social media and pharma: collaboration

The future of social media and pharma: collaboration

In Siren Interactive’s second of five rare disease articles, Katie Mihelich takes a look at pharma and patients’ use of social media. It’s hard to believe that popular social media has been a part of our lives for almost a decade now. This increased connectivity has…

Articles
Tunnah’s musings: lessons from listening to patients

Tunnah’s musings: lessons from listening to patients

As February sees pharmaphorum focus on patients, Paul Tunnah muses on what common lessons have already emerged for pharma from past patient interviews. If you have been following pharmaphorum in February you have probably noticed that we are focussing this month on ‘patients’ as our discipline focus, alongside …

Articles
Pharma gets social: world’s top pharma on Facebook

Pharma gets social: world’s top pharma on Facebook

Daniel Ghinn continues his series by looking at the Facebook social media strategies for the top 15 pharma companies. Among digital channels embraced or ignored by pharmaceutical companies, Facebook is associated with some of the most...

Sales & Marketing

Sales & Marketing
Solution Spotlight: BrandPRO Biopharma
Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Digital

Market Access

Market Access
Solution Spotlight: Acumetis Model Builder
Sponsored

Solution Spotlight: Acumetis Model Builder

Acumetis Model Builder is a web-based platform that generates complete, formula-linked Excel cost-effectiveness and budget impact models in minutes.

Editor's Picks

  1. Boehringer forges $7bn alliance with China's SBP Group News
  2. Lilly partners with Hims & Hers on obesity drug sales
  3. UK women's health firm Theramex sold for around £2.2bn
  4. What do midterms mean for Trump's pharma and health agenda?
  5. NICE backs Keytruda/Padcev combo for bladder cancer

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more